Skip to main content
All lobbying clients

ACADIA PHARMACEUTICALS, INC.

Lobbying client · California · filed 2025 to 2026

Biopharmaceutical company.

$4,830,000 Reported spend
29 Filings counted
4 Outside firms hired
11 Bills named

Spend is reported income plus in-house expenses across 29 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 5 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as ACADIA PHARMACEUTICALS, ACADIA PHARMACEUTICALS INC.

 Who filed for this client 5

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 11
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    11 filings
  • H.R. 1414
    Cameron’s Law
    7 filings
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    7 filings
  • H.R. 946
    ORPHAN Cures Act
    7 filings
  • H.R. 1
    One Big Beautiful Bill Act
    6 filings
  • H.R. 1509
    Accelerating Kids’ Access to Care Act of 2025
    6 filings
  • H.R. 3731
    Small Biotech Innovation Act
    6 filings
  • S. 932
    Give Kids a Chance Act of 2025
    4 filings
  • H.R. 6130
    ASAP Act
    3 filings
  • S. 3267
    ASAP Act
    3 filings
  • H.R. 9102
    BINSA Act
    2 filings
 Reported by year 2 years
  • 2026 $2,040,000 9 filings
  • 2025 $2,790,000 20 filings
 Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 7
  • HOUSE OF REPRESENTATIVES 27
  • SENATE 27
  • Food & Drug Administration (FDA) 4
  • Treasury, Dept of 4
  • Executive Office of the President (EOP) 3
  • Health & Human Services, Dept of (HHS) 3
  • Natl Economic Council (NEC) 1
 Recent filings 30 total
Q3 report
TIBER CREEK GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View →
Q3 report
ACADIA PHARMACEUTICALS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $440,000 expenses · posted Oct 19, 2026
View →
Q3 report
HOLLAND & KNIGHT LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 7, 2026
View →
Q2 report
ACADIA PHARMACEUTICALS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $700,000 expenses · posted Jul 20, 2026
View →
Q2 report
TIBER CREEK GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 19, 2026
View →
Q2 report
HOLLAND & KNIGHT LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 10, 2026
View →
Q1 report
ACADIA PHARMACEUTICALS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $600,000 expenses · posted Apr 20, 2026
View →
Q1 report
TIBER CREEK GROUP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 18, 2026
View →
Q4 termination
LMH STRATEGIC SOLUTIONS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Apr 16, 2026
View →
Q1 report
HOLLAND & KNIGHT LLP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $20,000 income · posted Apr 10, 2026
View →
Q4 termination
THE CONAFAY GROUP, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $10,000 income · posted Jan 20, 2026
View →
Q4 report
ACADIA PHARMACEUTICALS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $590,000 expenses · posted Jan 19, 2026
View →
Q4 report
TIBER CREEK GROUP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $80,000 income · posted Jan 17, 2026
View →
Q4 report
HOLLAND & KNIGHT LLP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $20,000 income · posted Jan 13, 2026
View →
Q4 report
LMH STRATEGIC SOLUTIONS Amended
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 12, 2026
View →
Q3 report
THE CONAFAY GROUP, LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 20, 2025
View →
Q3 report
LMH STRATEGIC SOLUTIONS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 20, 2025
View →
Q3 report
ACADIA PHARMACEUTICALS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $750,000 expenses · posted Oct 19, 2025
View →
Q3 report
TIBER CREEK GROUP
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 19, 2025
View →
Q3 report
HOLLAND & KNIGHT LLP
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 15, 2025
View →

Showing the 20 most recent of 30 filings. Search the explorer for "ACADIA PHARMACEUTICALS, INC.".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem